The investigational drug VERVE-101 uses CRISPR technology to target the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene, which regulates LDL levels. Study results indicate a significant reduction in LDL levels that may persist for many years.
Instead of taking daily medications, this one-time therapy may offer a new approach to lowering LDL levels. As research continues, scientists are optimistic about the potential of this gene-editing therapy to provide an alternative to current treatments for individuals with a genetic predisposition to high cholesterol.
News materials cannot be equated with a doctor’s prescription. Consult an expert before making a decision.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
